Exjade Novartis - Treatment for Chronic Iron Overload Due to Blood Transfusions
Exjade is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in adults and children age two and older.Posted: November 2005
Related articles
- FDA Approves Exjade to Remove Excess Iron in Patients with Genetic Blood Disorder - January 23, 2013
- FDA Advisory Committee Votes Unanimously to Recommend Approval of Exjade for Once-Daily Oral Treatment of Chronic Iron Overload Due to Blood Transfusions - September 29, 2005
- FDA Grants Priority Review for Exjade for the Treatment of Chronic Iron Overload Due to Blood Transfusions - June 22, 2005
- Novartis Files Exjade New Drug Applications for Treatment of Chronic Iron Overload Due to Blood Transfusions - May 3, 2005
Exjade (deferasirox) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
